News Insmed gets first FDA approval for bronchiectasis Insmed has claimed the distinction of getting the first FDA approval for a treatment for chronic lung disease non-cystic fibrosis bronchiectasis.
News PureTech launches lung disease specialist Celea PureTech launches Celea Therapeutics, tasked with bringing forward a drug that could offer a 'step change' in pulmonary fibrosis treatment.
News GSK forges $12bn alliance with China's Hengrui GSK has moved to shore up its R&D pipeline with a strategic-level partnering deal with China's Jiangsu Hengrui Pharma.
News Roche's COPD candidate fails a phase 3 readout Roche gambled on an all-comer design for trials of its COPD candidate astegolimab, a move that may prove costly as it fails a phase 3 test.
News Update: MSD confirms $10bn takeover deal for Verona Pharma MSD has agreed a $10bn takeover offer for respiratory drug specialist Verona Pharma and its fast-growing COPD therapy Ohtuvayre.
News GSK claims first approval for Nucala in COPD GSK gets FDA approval for Nucala in COPD, setting up a marketing tussle with Sanofi/Regeneron's Dupixent.
R&D Allogeneic cell therapy isn’t dead, with Brian Culley Lineage Cell Therapeutics' Brian Culley discusses allogeneic cell therapy, even beyond the traditional cell therapy realm of oncology.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.